

Supplementary Table 3. Responses of significantly altered metabolites among groups of patients with stage 2 or 3 AKI, healthy controls, and sepsis controls

No.	Metabolite	m/z (mass/charge)	Retention time (sec)	Stage 1 AKI	Stage 2 AKI	Stage 3 AKI	Healthy controls	Sepsis controls	Response	Mode	Trend <i>P</i> value*
1	Unannotated	325.18	14.68	18.78	18.09	18.08	18.87	19.2	Downregulated	C18 NEG	0.08
2	Unannotated	401.29	19.14	16.5	16.79	17.25	15.98	15.91	Upregulated	C18 NEG	0.01
3	1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine	452.28	15	18.54	18.72	19.25	18.22	18.16	Upregulated	C18 NEG	0.02
4	1-Oleoyl-sn-glycero-3-phosphoethanolamine	478.29	15.43	17.82	18.17	18.45	17.48	17.68	Upregulated	C18 NEG	0.01
5	1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine	480.31	16.91	19.37	19.75	20.13	19.2	19.14	Upregulated	C18 NEG	0.01
6	1-(5Z,8Z,11Z,14Z-Eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine	500.28	14.19	17.92	18.17	18.52	17.67	17.83	Upregulated	C18 NEG	0.01
7	Unannotated	524.28	13.97	17.03	17.14	17.68	16.53	16.58	Upregulated	C18 NEG	0.02

Values of stages 1, 2, and 3 AKI, sepsis, and healthy controls represent log fold changes.

*Spearman rank correlation statistical test

AKI, acute kidney injury; NEG, negative.